Please ensure Javascript is enabled for purposes of website accessibility
George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles


2 Penny Stocks That Could Make You Filthy Rich

AcelRx Pharmaceuticals and Sundial Growers could both be poised for a major growth spurt.

worried investor

Why Acadia Pharmaceuticals Stock Is Crashing Today

An unexpected regulatory setback is weighing on the biotech's shares.


Why Aurinia Pharmaceuticals Stock Is Flying Today

The FDA approved the drugmaker's closely watched lupus nephritis therapy.


Why Biohaven Pharmaceutical Stock Is Tanking Today

Alzheimer's claims another drug candidate.


Why Gritstone Oncology Is Bolting Higher Today

Gritstone's COVID-19 vaccine may have a critical role to play in halting the ongoing pandemic.

senior man

Why Eli Lilly Stock Is Crushing It Today

Investors are cheering Lilly's update in Alzheimer's disease today.

value v cost

2 Top Value Stocks to Own in 2021

AstraZeneca and Gilead Sciences should rebound nicely this year.

cannabis leaf american flag

Why Aurora Cannabis Is On Fire Today

A looming shift in the U.S. political landscape has pot investors cheering today.

genetic research

My Favorite Biotech Stock for 2021

This clinical-stage biotech stock could be a top buyout candidate in 2021.

Buy dice

2 Must-Own Stocks in 2021

American Airlines and Pfizer should both perform far better than expected in 2021.

Falling stock

Why uniQure Stock Is Tanking Today

A clinical hold is weighing on the biotech's shares today.


Why NantKwest Is Jumping Today

A merger agreement with a fellow immunotherapy company is exciting investors today.

cannabis leaf money

Why Aphria and Tilray Are Soaring Today

Aphria and Tilray are moving toward a landmark merger agreement.


Why Alexion Pharmaceuticals Is Soaring and AstraZeneca Is Sinking Today

Alexion finally gets taken out.


Why Five Prime Therapeutics Stock Gained 312% in November

This tiny biotech might be developing a major new cancer drug.

CV upclose

Why Novavax Stock Crushed It in November

A rival's setback could translate into a major windfall for this mid-cap biotech company.

cannabis leaf american flag

Why Aurora Cannabis Stock Rocketed Higher in November

The mere possibility of cannabis reform in the U.S. sent this pot stock screaming higher last month.

COVID vaccine globe

Why Moderna and Novavax Shares Are Racing Higher Today

AstraZeneca's slip is sending these two biotechs higher today.


Why Sorrento Therapeutics Stock Is Ripping Higher Today

The biotech's COVID-19 pipeline lands a major vote of confidence.

surprised girl money flying

3 Stocks with Jaw-Dropping Growth Potential

Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.